文献速递膀胱癌与上尿路尿路上皮癌

BCG治疗期间传统及表达PD-L1的调节性T细胞富集并可能限制其疗效

Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
PubMed 文献 · Eur Urol · 2018-07-19

本研究前瞻性评估接受BCG治疗的尿路上皮癌患者血液和尿液中传统调节性T细胞(cTregs)及表达PD-L1的CD4 T细胞(PD-L1+ Tregs)水平。发现局部cTregs频率高于外周,且尿液中PD-L1+ Tregs显著存在,BCG感染尿路上皮细胞可部分通过干扰素-β机制诱导PD-L1+ Tregs。尿液中高Tregs水平与BCG治疗后快速复发相关,提示联合PD-1/PD-L1检查点抑制剂可能是有前景的策略。

要点

  • BCG治疗期间尿液中cTregs和PD-L1+ Tregs富集。
  • 尿液中高Tregs水平与BCG治疗后快速复发相关。
  • BCG联合PD-1/PD-L1抑制剂可能提高非肌层浸润性膀胱癌疗效。

核心结论

  • BCG治疗期间募集的T淋巴细胞包含显著比例的调节性细胞,包括非经典来源的PD-L1,可能限制BCG疗效。

研究设计与样本

  • 前瞻性研究,评估接受BCG治疗的尿路上皮癌患者血液和尿液中cTregs和PD-L1+ Tregs水平。

主要发现

  • 局部cTregs频率高于外周对应细胞,且体外可由膀胱肿瘤细胞诱导。
  • 健康供者和尿路上皮癌患者血液中几乎检测不到PD-L1+ Tregs,但患者尿液中存在大量PD-L1+ Tregs。
  • 体外实验提示BCG感染尿路上皮细胞可部分通过干扰素-β介导机制诱导PD-L1+ Tregs。
  • 尿液中高Tregs水平与BCG治疗后快速复发相关。

临床怎么用

  • 尿液中Tregs水平可能作为BCG治疗后复发的预测指标。
  • BCG联合PD-1/PD-L1检查点抑制剂是治疗非肌层浸润性膀胱癌的有前景策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The regulation of immune responses occurring during Bacillus Calmette-Guerin (BCG) therapy need to be better scrutinized in order to identify new targetable pathways for non-muscle invasive bladder cancer treatment. Immunoregulatory mechanisms have emerged as key players in various cancers. While T lymphocytes are crucial for the control of tumor growth, they often include regulatory subsets known to restrain their anti-tumor activity. In this prospective study, we assessed conventional regulatory T cells (cTregs) and PD-L1-expressing CD4 T cells (PD-L1+ Tregs) levels in blood and urine of urothelial cancer (UCa) patients undergoing BCG treatment. Local cTregs were found at higher frequencies than their counterpart in the periphery and induced by bladder tumor cells in vitro. Interestingly, while circulating PD-L1+ Tregs were hardly detectable in the blood of healthy donors and UCa patients, substantial levels were found in patients' urine. In vitro experiments suggested that BCG infection of urothelial cells could induce PD-L1+ Tregs, partially via an interferon-β-mediated mechanism. Of note, high level of Tregs in urine was associated with rapid recurrence following BCG therapy. Our findings demonstrate that T lymphocytes recruited during BCG therapy encompass a significant fraction of regulatory cells including a non-classical source of PD-L1 and reinforce treatment strategies combining BCG with PD-1/PD-L1 checkpoint inhibitors as promising approaches for non-muscle invasive bladder cancer. PATIENT SUMMARY: We investigated the presence of particular immune cell types in the urine of bladder cancer patients undergoing Bacillus Calmette-Guerin (BCG) therapy. We identified a cell type that is strongly enriched in the urine after BCG instillation and that may favor tumor recurrence. This immune subpopulation might be targeted for bladder cancer treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chevalier MF, Schneider AK, Cesson V, et al. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. Eur Urol. 2018. PMID: 30033046. doi:10.1016/j.eururo.2018.06.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。